Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Peter Cummings

Orthopaedic Surgery Phoenix, AZ Medical Doctor

NPI 1942285978 CMS profile 178649

2222 E Highland Ave, Ste 300, Phoenix, AZ 85016

Open in the dashboard

General payments

$139,632

266 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$5,141 paid to institutions, not to them · program years 2019–2020

Through program year 2025, Peter Cummings of Phoenix, AZ is reported in the CMS Open Payments database as having received $139,632 across 266 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $5,141 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 93rd percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $45,912 62
2024 General $8,120 7
2023 General $9,719 7
2022 General $11,317 23
2021 General $13,564 10
2020 General $13,364 45
2019 General $37,636 112

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Peter Cummings
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Peter Cummings were reported at $45,912. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Peter Cummings Orthopaedic Surgery median Middle half National median
2019 $37,636 $644 $140–$2,844 $163
2020 $13,364 $312 $75–$1,860 $114
2021 $13,564 $520 $117–$2,495 $132
2022 $11,317 $598 $128–$2,731 $149
2023 $9,719 $461 $128–$2,264 $160
2024 $8,120 $497 $134–$2,475 $164
2025 $45,912 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Zimmer Biomet Holdings, Inc. $97,617 55 payments
  2. Amgen Inc. $40,040 103 payments
  3. Radius Health, Inc. $356 31 payments
  4. Horizon Therapeutics plc $273 36 payments
  5. Anika Therapeutics, Inc. $171 1 payment
  6. Ferring Pharmaceuticals Inc. $153 9 payments
  7. Abbott Laboratories $138 1 payment
  8. Smith+Nephew, Inc. $124 6 payments
  9. Arthrex, Inc. $121 1 payment
  10. Arthrosurface Incorporated $108 1 payment
  11. Other $532 22 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $81,002 27 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $28,759 16 payments
  3. Consulting Fee $14,250 9 payments
  4. Travel and Lodging $10,751 28 payments
  5. Food and Beverage $4,845 185 payments
  6. Education $24 1 payment
Products named General payments · program years 2019–2025
  1. Biowick Sports Medicine $44,673 18 payments
  2. BioWick X $35,165 16 payments
  3. EVENITY $32,369 87 payments
  4. Biowick Sports Medicine $13,251 4 payments
  5. AperFix Femoral Fixation $10,771 7 payments
  6. AperFix II Tibial Fixation $10,663 6 payments
  7. Prolia $704 46 payments
  8. Juggerknot $463 3 payments
  9. Tymlos $323 30 payments
  10. DUEXIS $195 27 payments
  11. Other $1,671 60 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$80,016

Of which drugs: $22,489

Medicare patients

276

Average age 73

Services billed

1,468

139 women, 137 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 61%
Osteoporosis 31%
Ischemic heart disease 22%
Diabetes 21%
Chronic kidney disease 21%
Cancer 18%
Depression 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose J7324 Office 33 132 $12,709
Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose J7323 Office 12 46 $4,134
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 64 382 $1,992

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

266 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record